Upgrade to SI Premium - Free Trial

BofA Securities on Sarepta Therapeutics (SRPT): sNDAs 'positive first step' but regulatory risk continues

March 19, 2026 11:11 AM
BofA Securities analyst Tazeen Ahmad reiterated an Underperform rating and $19.00 price target on Sarepta Therapeutics (NASDAQ: SRPT)The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments